| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0091270004265644 |
| P698 | PubMed publication ID | 15145966 |
| P2093 | author name string | James A Dowell | |
| Tom Ludden | |||
| William Knebel | |||
| David Krause | |||
| Marty Stogniew | |||
| Tim Henkel | |||
| P2860 | cites work | New drugs and novel targets for treatment of invasive fungal infections in patients with cancer | Q33905634 |
| In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species | Q43563885 | ||
| Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method | Q44257296 | ||
| In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. | Q44340936 | ||
| P433 | issue | 6 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 590-598 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal | |
| P478 | volume | 44 |
| Q40635237 | A Comparative Study of the Effects of Intravitreal Anidulafungin, Voriconazole, and Amphotericin B in an Experimental Candida Endophthalmitis Model |
| Q38419657 | A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. |
| Q45084559 | Anidulafungin |
| Q42731827 | Anidulafungin and its role in candida infections |
| Q33490772 | Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination |
| Q35689202 | Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. |
| Q36822941 | Anidulafungin in the treatment of invasive fungal infections |
| Q37327122 | Anidulafungin in the treatment of patients with invasive candidiasis |
| Q35127833 | Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis |
| Q51339243 | Anidulafungin--challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies. |
| Q36774257 | Anidulafungin--state of affairs from a clinical perspective. |
| Q36723788 | Anidulafungin: a new echinocandin for candidal infections |
| Q46600233 | Anidulafungin: a new echinocandin for the treatment of mycosis |
| Q43449387 | Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin |
| Q37345790 | Anidulafungin: a novel echinocandin for candida infections |
| Q37827345 | Anidulafungin: an evidence-based review of its use in invasive fungal infections. |
| Q37854724 | Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections? |
| Q35917456 | Anidulafungin: review of a new echinocandin antifungal agent |
| Q36948094 | Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective |
| Q37310029 | Antifungal therapeutic drug monitoring: established and emerging indications |
| Q43287630 | Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections |
| Q45221761 | Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine |
| Q37450705 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults |
| Q42111965 | Cardiac effects of echinocandins after central venous administration in adult rats |
| Q38586680 | Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes |
| Q90737374 | Choosing the Right Antifungal Agent in ICU Patients |
| Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
| Q35892563 | Clinically relevant drug-drug interactions between antiretrovirals and antifungals |
| Q28273738 | Comparison of echinocandin antifungals |
| Q43251797 | Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections |
| Q38284468 | Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. |
| Q37253669 | Does Weight Impact Anidulafungin Pharmacokinetics? |
| Q36222035 | Echinocandins: role in antifungal therapy, 2005. |
| Q37578555 | Effects of echinocandin preparations on adult rat ventricular cardiomyocytes. Preliminary results of an in vitro study |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q48192025 | Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro |
| Q58033533 | Glucan Synthase Inhibitors |
| Q37904672 | Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. |
| Q35070838 | Human pharmacogenomic variations and their implications for antifungal efficacy |
| Q38462784 | Impact of special patient populations on the pharmacokinetics of echinocandins. |
| Q42111638 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| Q43169846 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin |
| Q39077602 | In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. |
| Q36425025 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| Q37719545 | Interactions between antifungal and antiretroviral agents |
| Q42612968 | Lack of pharmacokinetic interaction between anidulafungin and tacrolimus |
| Q37544395 | Low but sufficient anidulafungin exposure in critically ill patients |
| Q37632290 | Mycoses in the elderly |
| Q48149179 | New Horizons in Antifungal Therapy. |
| Q36640752 | PXR antagonists and implication in drug metabolism |
| Q35270758 | Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts |
| Q39020129 | Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis |
| Q33827819 | Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology |
| Q36505301 | Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection. |
| Q27025299 | Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications |
| Q37612946 | Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections |
| Q64898954 | Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. |
| Q36163345 | Pharmacokinetics of antifungal agents in children |
| Q38681635 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients |
| Q37785979 | Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections |
| Q57746174 | Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins |
| Q37624716 | Pharmacological properties of antifungal drugs with a focus on anidulafungin |
| Q37359613 | Pharmacology and antifungal properties of anidulafungin, a new echinocandin |
| Q57533011 | Pharmacology of Systemic Antifungal Agents |
| Q40488737 | Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer |
| Q52648080 | Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data. |
| Q91803509 | Population Pharmacokinetics of Anidulafungin in Critically Ill Patients |
| Q90441453 | Population analysis of anidulafungin in infants to older adults with confirmed or suspected invasive candidiasis |
| Q34058346 | Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis |
| Q36505401 | Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections |
| Q34054746 | Quantitative analysis of the antifungal drug anidulafungin by LC-online SPE-MS/MS in human plasma |
| Q46807629 | Safety and pharmacokinetics of coadministered voriconazole and anidulafungin |
| Q34352100 | Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections |
| Q35071572 | Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates |
| Q36742397 | The echinocandins |
| Q36626518 | The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications |
| Q46600214 | The role of anidulafungin therapy in solid organ transplant recipients |
| Q36624970 | The safety of anidulafungin |
| Q37985070 | The use of antifungal therapy in neonatal intensive care. |
| Q38738090 | Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations |
| Q46600220 | Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis |
| Q48670237 | Tissue distribution of anidulafungin in neonatal rats. |
| Q27001567 | Treatment and prophylaxis of invasive candidiasis |
| Q35959489 | Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature |
| Q37255172 | Treatment of invasive candidiasis in immunocompromised pediatric patients |
| Q38073201 | Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review |
| Q86999162 | [Liver dysfunctions in intensive care patients--consequences for the treatment of invasive Candida infections] |
| Q54570872 | [Pharmacokinetic interactions]. |
| Q45942595 | [Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins]. |
| Q45942588 | [Role of anidulafungin in solid organ transplant recipients]. |
Search more.